Market News
- Everolimus by Novartis for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 18, 2024
Everolimus is under clinical development by Novartis and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
- Ramucirumab by Eli Lilly and Co for Gallbladder Cancer: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 18, 2024
Ramucirumab is under clinical development by Eli Lilly and Co and currently in Phase II for Gallbladder Cancer.
- Everolimus by Novartis for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 18, 2024
Everolimus is under clinical development by Novartis and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
- Abatacept by Bristol-Myers Squibb for Myocarditis: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 18, 2024
Abatacept is under clinical development by Bristol-Myers Squibb and currently in Phase III for Myocarditis.
- Estetrol by Mithra Pharmaceuticals for Genitourinary Syndrome of Menopause (GSM): Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 18, 2024
Estetrol is under clinical development by Mithra Pharmaceuticals and currently in Phase III for Genitourinary Syndrome of Menopause (GSM).
- Estetrol by Mithra Pharmaceuticals for Female Sexual Dysfunction: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 18, 2024
Estetrol is under clinical development by Mithra Pharmaceuticals and currently in Phase II for Female Sexual Dysfunction.
- Paclitaxel albumin bound by Bristol-Myers Squibb for Pancreatic Ductal Adenocarcinoma: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 18, 2024
Paclitaxel albumin bound is under clinical development by Bristol-Myers Squibb and currently in Phase I for Pancreatic Ductal Adenocarcinoma.
- Paclitaxel albumin bound by Bristol-Myers Squibb for Gallbladder Cancer: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 18, 2024
Paclitaxel albumin bound is under clinical development by Bristol-Myers Squibb and currently in Phase III for Gallbladder Cancer.
- Tezepelumab by Amgen for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 18, 2024
Tezepelumab is under clinical development by Amgen and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD).
- Belumosudil mesylate by Sanofi for Lung Transplant Rejection: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 18, 2024
Belumosudil mesylate is under clinical development by Sanofi and currently in Phase III for Lung Transplant Rejection.
- Pharmaceutical Executive: April 2024 Issue (PDF)by OncLive articles on April 17, 2024
Click the title above for a link to open the Pharmaceutical Executive April 2024 issue in an interactive PDF format.
- GSK’s Five-in-One Meningococcal Vaccine Under Review by the FDAby OncLive articles on April 17, 2024
With a final decision expected next February, MenABCWY combines the protective elements of GSK’s existing vaccines to target the five primary serogroups of Neisseria meningitidis.
- Power in Partneringby OncLive articles on April 17, 2024
Efforts to partner and collaborate within the life sciences industry—and externally with governments, regulators, and others—have taken on added weight in recent years.
- Lilly obesity drug shows benefit in sleep disorder study, pointing to new useby Jonathan Gardner (BioPharma Dive – Latest News) on April 17, 2024
Positive data for Lilly’s medicine tirzepatide in sleep apnea are the latest signal the benefits of GLP-1 agonists could extend beyond diabetes and weight loss.
- Sage’s cognition drug fails in Parkinson’s studyby Jacob Bell (BioPharma Dive – Latest News) on April 17, 2024
Following negative results, the company doesn’t plan to further test SAGE-718 in Parkinson’s. Other studies in Huntington’s and Alzheimer’s remain ongoing.
- Stelara biosimilar from Alvotech, Teva approved by FDAby Kristin Jensen (BioPharma Dive – Latest News) on April 17, 2024
The companies plan to launch their copycat version of the blockbuster immune disease drug early next year, per a legal settlement with J&J.
- UniDoc Brings AI-Powered Health Cube to Alaskaby OncLive articles on April 17, 2024
The Health Cube will increase remote and virtual care options for populations living in remote areas.
- Canaan hires Pfizer executive, reels in $100M for biotech investingby Gwendolyn Wu (BioPharma Dive – Latest News) on April 17, 2024
The firm has brought in as venture partner Uwe Schoenbeck, who most recently was the top scientist for Pfizer’s emerging science and innovation unit.
- FDA Approves Stelara Biosimilar Selarsdi to Treat Psoriasis, Psoriatic Arthritisby OncLive articles on April 17, 2024
Alvotech’s and Teva’s Selarsdi (ustekinumab-aekn), the second FDA-approved biosimilar to Stelara, is indicated to treat patients aged 6 years and above with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic […]
- Novo Nordisk Foundation Executive Talks Biomedical Quantum Sensingby OncLive articles on April 17, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Lene Oddershede, SVP, Natural & Technical Sciences, Novo Nordisk Foundation discusses a recent grant awarded to the Copenhagen Center for Biomedical Quantum Sensing.